The Labeling, Visualization, and Quantification of Hyaluronan Distribution in Tumor-Bearing Mouse Using PET and MR Imaging

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2020 Nov 5

PMID 33151373

Authors

Wangxi Hai

Xiao Bao

Kang Sun

Biao Li

Jinliang Peng

Yuhong Xu

Affiliations

Soon will be listed here.

Abstract

Purpose: Hyaluronan (HA) based biomaterials are widely used as tissue scaffolds, drug formulations, as well as targeting ligands and imaging probes for diagnosis and drug delivery. However, because of the presence of abundant endogenous HA presented in various tissues in vivo, the pharmacokinetic behavior and biodistribution patterns of exogenously administered HAs have not been well characterized.

Methods: The HA backbone was modified with Diethylenetriamine (DTPA) to enable the chelation of gadolinium (Gd) and aluminum (Al) ions. Series of PET and MR imaging were taken after the injection of HA-DTPA-Gd and HA-DTPA-AlF while usingF-FDG and Magnevist(DTPA-Gd) as controls. The Tomographic images were analyzed and quantified to reveal the distribution and locations of HA in tumor-bearing mice.

Results: The labeled HAs had good stability in plasma. They retained binding affinity towards CD44s on tumor cell surface. The injected HAs distributed widely in various organs, but were found to be cleared quickly except inside tumor tissues where the signals were higher and persisted longer.

Conclusion: Medical imaging tools, including MR and PET, can be highly valuable for examining biomaterial distribution non-invasively. The HA tumor accumulation properties may be explored for the development of active targeting drug carriers and molecular probes.

References

Fraser J, Laurent T, Laurent U . Hyaluronan: its nature, distribution, functions and turnover. J Intern Med. 1997; 242(1):27-33. DOI: 10.1046/j.1365-2796.1997.00170.x. View

Crescenzi V, Francescangeli A, Renier D, Bellini D . New cross-linked and sulfated derivatives of partially deacetylated hyaluronan: synthesis and preliminary characterization. Biopolymers. 2002; 64(2):86-94. DOI: 10.1002/bip.10131. View

Pulakkat S, Balaji S, Rangarajan A, Raichur A . Surface Engineered Protein Nanoparticles With Hyaluronic Acid Based Multilayers For Targeted Delivery Of Anticancer Agents. ACS Appl Mater Interfaces. 2016; 8(36):23437-49. DOI: 10.1021/acsami.6b04179. View

Goodarzi N, Ghahremani M, Amini M, Atyabi F, Ostad S, Ravari N . CD44-targeted docetaxel conjugate for cancer cells and cancer stem-like cells: a novel hyaluronic acid-based drug delivery system. Chem Biol Drug Des. 2014; 83(6):741-52. DOI: 10.1111/cbdd.12288. View

Maiolino S, Moret F, Conte C, Fraix A, Tirino P, Ungaro F . Hyaluronan-decorated polymer nanoparticles targeting the CD44 receptor for the combined photo/chemo-therapy of cancer. Nanoscale. 2015; 7(13):5643-53. DOI: 10.1039/c4nr06910b. View

Misra S, Hascall V, Markwald R, Ghatak S . Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer. Front Immunol. 2015; 6:201. PMC: 4422082. DOI: 10.3389/fimmu.2015.00201. View

Chanmee T, Ontong P, Kimata K, Itano N . Key Roles of Hyaluronan and Its CD44 Receptor in the Stemness and Survival of Cancer Stem Cells. Front Oncol. 2015; 5:180. PMC: 4530590. DOI: 10.3389/fonc.2015.00180. View

Yan Y, Zuo X, Wei D . Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. Stem Cells Transl Med. 2015; 4(9):1033-43. PMC: 4542874. DOI: 10.5966/sctm.2015-0048. View

Song J, Im J, Nho R, Han Y, Upadhyaya P, Kassie F . Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells. Mol Carcinog. 2018; 58(3):321-333. PMC: 11005861. DOI: 10.1002/mc.22930. View

10.

Sun S, Wu C, Sheu G, Chang H, Chen M, Lin Y . Integrin β3 and CD44 levels determine the effects of the OPN-a splicing variant on lung cancer cell growth. Oncotarget. 2016; 7(34):55572-55584. PMC: 5342437. DOI: 10.18632/oncotarget.10865. View

11.

van der Voort R, Manten-Horst E, Smit L, Ostermann E, van den Berg F, Pals S . Binding of cell-surface expressed CD44 to hyaluronate is dependent on splicing and cell type. Biochem Biophys Res Commun. 1995; 214(1):137-44. DOI: 10.1006/bbrc.1995.2267. View

12.

Vugts D, Heuveling D, Stigter-van Walsum M, Weigand S, Bergstrom M, van Dongen G . Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies. MAbs. 2014; 6(2):567-75. PMC: 3984344. DOI: 10.4161/mabs.27415. View

13.

Isacke C, Yarwood H . The hyaluronan receptor, CD44. Int J Biochem Cell Biol. 2002; 34(7):718-21. DOI: 10.1016/s1357-2725(01)00166-2. View

14.

Platt V, Szoka Jr F . Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm. 2008; 5(4):474-86. PMC: 2772999. DOI: 10.1021/mp800024g. View

15.

Battistini F, Flores-Martin J, Olivera M, Genti-Raimondi S, Manzo R . Hyaluronan as drug carrier. The in vitro efficacy and selectivity of Hyaluronan-Doxorubicin complexes to affect the viability of overexpressing CD44 receptor cells. Eur J Pharm Sci. 2014; 65:122-9. DOI: 10.1016/j.ejps.2014.09.008. View

16.

Cho H, Yoon H, Koo H, Ko S, Shim J, Cho J . Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis. J Control Release. 2012; 162(1):111-8. DOI: 10.1016/j.jconrel.2012.06.011. View

17.

Lee J, Chung S, Cho H, Kim D . Iodinated hyaluronic acid oligomer-based nanoassemblies for tumor-targeted drug delivery and cancer imaging. Biomaterials. 2016; 85:218-31. DOI: 10.1016/j.biomaterials.2016.01.060. View

18.

Wang L, Draz M, Wang W, Liao G, Xu Y . The Quality of In Vivo Upconversion Fluorescence Signals Inside Different Anatomic Structures. J Biomed Nanotechnol. 2015; 11(2):325-33. DOI: 10.1166/jbn.2015.1947. View

19.

Pichler B, Kolb A, Nagele T, Schlemmer H . PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med. 2010; 51(3):333-6. DOI: 10.2967/jnumed.109.061853. View

20.

Blanchet E, Millo C, Martucci V, Maass-Moreno R, Bluemke D, Pacak K . Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol. Clin Nucl Med. 2013; 39(3):243-50. PMC: 5539761. DOI: 10.1097/RLU.0000000000000289. View